Sulfonylurea

Studies showed that mono therapy of metformin had 85% fewer deaths and hospitalizations then sulfonylurea.

ACE inhibitors may cause a temporary increase of the insulin sensitivity, which leads to an increased risk of hypoglycemia.

Although the addition of sulfonylureas to metformin therapy improves glycemic control in type 2 diabetics, deterioration may resume in as little 6 months’

After 6 months deterioration of glycemic control resumes following the addition of SUs to MF.

Glycemic control is improved following the addition of SUs to MF, but deterioration resumes as early as 6 months.

Continuous sulfonylurea exposure over a certain level impairs rather than improves insulin and glucose responses to sulfonylurea.

A greater then a 1% drop in A1c was resulted from using piogliazone with metformin then glyburide with metformin.

Early addition of the insulin sensitizer rosiglitazone (Avandia) in older type 2 diabetic patients previously on submaximal doses of a sulfonylurea reduces disease progression and provides superior glycemic control that is sustained over two years.

A study suggests that sulfonylurea oral diabetes medications may be linked to increased risk of coronary artery spasms.